Clinical Trials

Phase 1 Not yet recruiting

Brain Neoplasms, Breast Neoplasms

NCT07454668 2026-03-06

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

20 enrolled

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05376878 2026-02-23

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Phase 4 Recruiting

10 enrolled

Brain Neoplasms, Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07368543 2026-01-28

STORM

216 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT05633979 2026-01-20

Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer

17 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06663787 2025-11-28

HER2 CR

Active not recruiting

50 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

88 enrolled

Breast Neoplasms

NCT06533826 2025-10-24

TRADE DXd

357 enrolled

Breast Neoplasms

NCT06504719 2025-09-15

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

Completed

312 enrolled

Phase 2 Not yet recruiting

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis

NCT07151586 2025-09-03

ALTER

260 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT07134153 2025-08-21

INOVATE

Phase 1/2 Recruiting

139 enrolled

Breast Neoplasms

NCT06172127 2025-07-29

DEMETHER

165 enrolled

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT04420598 2025-06-24

DEBBRAH

Phase 2 Completed

41 enrolled 32 charts

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT07030569 2025-06-22

RADIOSPHER2

Recruiting

500 enrolled

Breast Neoplasms

NCT04132960 2025-06-12

DAISY

Phase 2 Completed

186 enrolled

Breast Neoplasms

NCT06643585 2025-05-02

SURVIVE HERoes

Phase 3 Recruiting

180 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06797622 2025-01-28

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

50 enrolled

Breast Neoplasms

NCT06551220 2024-12-04

HEROIC

Recruiting

800 enrolled

Breast Neoplasms

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1 Recruiting

42 enrolled

Breast Neoplasms

NCT06328387 2024-03-25

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Phase 1/2 Recruiting

120 enrolled

Phase 4 Not yet recruiting

Breast Neoplasms

NCT06245824 2024-02-07

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

51 enrolled

Breast Neoplasms

NCT06135194 2023-11-18

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Unknown

30 enrolled

Breast Neoplasms

NCT04752059 2023-05-12

TUXEDO-1

Phase 2 Completed

15 enrolled

Breast Neoplasms

NCT05594082 2023-04-04

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

Unknown

150 enrolled